Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
File this under ‘Life’s little ironies.” Last week, an FDA advisory panel voted against recommending a drug called Tolvaptan for treating ADPKD, a rare disease in which numerous cysts grow in kidneys. The reasons for rejecting the drug, which is already approved to combat low blood sodium levels, were unanswered questions about efficacy and, in particular, safety concerns over liver toxicity. There was, however, an interesting subtext to the meeting.
Help employers find you! Check out all the jobs and post your resume.
